BACKGROUND AND PURPOSE: The phytocannabinoid Delta(9)-tetrahydrocannabivarin (Delta(9)-THCV) has been reported to exhibit a diverse pharmacology; here, we investigate functional effects of Delta(9)-THCV, extracted from Cannabis sativa, using electrophysiological techniques to define its mechanism of action in the CNS. EXPERIMENTAL APPROACH: Effects of Delta(9)-THCV and synthetic cannabinoid agents on inhibitory neurotransmission at interneurone-Purkinje cell (IN-PC) synapses were correlated with effects on spontaneous PC output using single-cell and multi-electrode array (MEA) electrophysiological recordings respectively, in mouse cerebellar brain slices in vitro. KEY RESULTS: The cannabinoid receptor agonist WIN 55,212-2 (WIN55) decreased miniature inhibitory postsynaptic current (mIPSC) frequency at IN-PC synapses. WIN55-induced inhibition was reversed by Delta(9)-THCV, and also by the CB(1) receptor antagonist AM251; Delta(9)-THCV or AM251 acted to increase mIPSC frequency beyond basal values. When applied alone, Delta(9)-THCV, AM251 or rimonabant increased mIPSC frequency. Pre-incubation with Delta(9)-THCV blocked WIN55-induced inhibition. In MEA recordings, WIN55 increased PC spike firing rate; Delta(9)-THCV and AM251 acted in the opposite direction to decrease spike firing. The effects of Delta(9)-THCV and WIN55 were attenuated by the GABA(A) receptor antagonist bicuculline methiodide. CONCLUSIONS AND IMPLICATIONS: We show for the first time that Delta(9)-THCV acts as a functional CB(1) receptor antagonist in the CNS to modulate inhibitory neurotransmission at IN-PC synapses and spontaneous PC output. Delta(9)-THCV- and AM251-induced increases in mIPSC frequency beyond basal levels were consistent with basal CB(1) receptor activity. WIN55-induced increases in PC spike firing rate were consistent with synaptic disinhibition; whilst Delta(9)-THCV- and AM251-induced decreases in spike firing suggest a mechanism of PC inhibition.
BACKGROUND AND PURPOSE: The phytocannabinoidDelta(9)-tetrahydrocannabivarin (Delta(9)-THCV) has been reported to exhibit a diverse pharmacology; here, we investigate functional effects of Delta(9)-THCV, extracted from Cannabis sativa, using electrophysiological techniques to define its mechanism of action in the CNS. EXPERIMENTAL APPROACH: Effects of Delta(9)-THCV and synthetic cannabinoid agents on inhibitory neurotransmission at interneurone-Purkinje cell (IN-PC) synapses were correlated with effects on spontaneous PC output using single-cell and multi-electrode array (MEA) electrophysiological recordings respectively, in mouse cerebellar brain slices in vitro. KEY RESULTS: The cannabinoid receptor agonist WIN 55,212-2 (WIN55) decreased miniature inhibitory postsynaptic current (mIPSC) frequency at IN-PC synapses. WIN55-induced inhibition was reversed by Delta(9)-THCV, and also by the CB(1) receptor antagonist AM251; Delta(9)-THCV or AM251 acted to increase mIPSC frequency beyond basal values. When applied alone, Delta(9)-THCV, AM251 or rimonabant increased mIPSC frequency. Pre-incubation with Delta(9)-THCV blocked WIN55-induced inhibition. In MEA recordings, WIN55 increased PC spike firing rate; Delta(9)-THCV and AM251 acted in the opposite direction to decrease spike firing. The effects of Delta(9)-THCV and WIN55 were attenuated by the GABA(A) receptor antagonist bicuculline methiodide. CONCLUSIONS AND IMPLICATIONS: We show for the first time that Delta(9)-THCV acts as a functional CB(1) receptor antagonist in the CNS to modulate inhibitory neurotransmission at IN-PC synapses and spontaneous PC output. Delta(9)-THCV- and AM251-induced increases in mIPSC frequency beyond basal levels were consistent with basal CB(1) receptor activity. WIN55-induced increases in PC spike firing rate were consistent with synaptic disinhibition; whilst Delta(9)-THCV- and AM251-induced decreases in spike firing suggest a mechanism of PC inhibition.
Authors: M Bouaboula; S Perrachon; L Milligan; X Canat; M Rinaldi-Carmona; M Portier; F Barth; B Calandra; F Pecceu; J Lupker; J P Maffrand; G Le Fur; P Casellas Journal: J Biol Chem Date: 1997-08-29 Impact factor: 5.157
Authors: Allyn C Howlett; Christopher S Breivogel; Steven R Childers; Samuel A Deadwyler; Robert E Hampson; Linda J Porrino Journal: Neuropharmacology Date: 2004 Impact factor: 5.250
Authors: Jonathan A Farrimond; Andrew J Hill; Benjamin J Whalley; Claire M Williams Journal: Psychopharmacology (Berl) Date: 2010-03-27 Impact factor: 4.530
Authors: Ann K Shinn; Youkyung S Roh; Caitlin T Ravichandran; Justin T Baker; Dost Öngür; Bruce M Cohen Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-07
Authors: Daniele Bolognini; Barbara Costa; Sabatino Maione; Francesca Comelli; Pietro Marini; Vincenzo Di Marzo; Daniela Parolaro; Ruth A Ross; Lisa A Gauson; Maria G Cascio; Roger G Pertwee Journal: Br J Pharmacol Date: 2010-06 Impact factor: 8.739
Authors: Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens Journal: J Pharmacol Exp Ther Date: 2009-11-11 Impact factor: 4.030